GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.

Brii Bio’s COVID-19 Antibody Cocktail Sees Promising Results in Phase 3 ACTIV-2 Trial

by Joy Lin
Share To

Early data from a Phase 3 clinical trial investigating Brii Biosciences’ monoclonal antibody combination treatment is looking good. The company announced on August 24th, that its antibody cocktail reduced the risk of hospitalization and death in non-hospitalized patients by 78%.

The Phase 3 ACTIV-2 trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). In addition to Brii, the trial includes notable collaborators in Eli Lilly, AstraZeneca, and Bristol-Myers Squibb.

The COVID-19 treatment under investigation is a combination of Brii-developed monoclonal antibodies BRII-196 and BRII-198. In vitro evidence suggests the combination possesses high neutralization activity against multiple COVID-19 variants.

The ACTIV-2 study evaluated 837 patients whose disease had not progressed to the point of hospitalization but was at high risk of serious illness.

Only 12 patients given Brii’s combo ended up in the hospital, compared to 45 in the placebo group. Furthermore, only one patient in the active group died, compared to 9 in the placebo group. The treatment did not cause more serious adverse events compared to the placebo.

Further analysis is needed to compare the effectiveness of an early (≤5 days)  or late (6-10 days) treatment following the onset of symptoms.

Related Article: ExeVir Bio’s COVID-19 Neutralizing Antibody Derived From Llamas Advances to Phase 1 Trials

 

The Earlier The Better

 

The answer is clear, however, that an earlier deployment beats a later one.

Neither Brii’s combination treatment nor Eli Lilly solo antibody treatment bamlanivimab survived the NIH-funded ACTIV-3 trial when the drugs showed little benefit in treating hospitalized COVID-19 patients.

To date, the only antibody cocktail that is approved to treat hospitalized COVID-19 patients is Regeneron’s Ronapreve, also known as REGEN-COV. The treatment administering casirivimab and imdevimab together also recently became the first monoclonal antibody therapy against COVID-19 to be approved in Europe.  

Other treatments for hospitalized patients with advanced symptoms include the steroid dexamethasone and remdesivir, an antiviral drug.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Sanofi and AstraZeneca’s RSV Antibody Drug Gets FDA Approval, Adding New Weapon for Preventing Infant Infections
2023-07-18
Jounce Sells Anti-CCR8 Antibody to Gilead, Forgoing $645 Million In Milestones
2022-12-28
AstraZeneca’s Treatment for COVID-19 Wins European Approval
2022-09-20
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top